The nature and biology of basement membranes

Matrix Biology

Volumn 57-58, Issue , 2017, Pages 1-11

  Pozzi, Ambra ^a,d   Yurchenco, Peter D ^b   Iozzo, Renato V ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Veterans Affairs Hospitals   (United States)

Author keywords

Collagen; Discoidin domain receptor; Heparan sulfate proteoglycan; Integrin; Laminin

Indexed keywords

BASEMENT MEMBRANE; EMBRYO DEVELOPMENT; HUMAN; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BONE DYSPLASIA; CHEMISTRY; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETICS; LUPUS ERYTHEMATOSUS NEPHRITIS; MECHANOTRANSDUCTION; METABOLISM; MUTATION; PATHOLOGY;

AGRIN; COLLAGEN TYPE 4; ENTACTIN; ISOPROTEIN; LAMININ; MEMBRANE PROTEIN; PROTEOHEPARAN SULFATE;

AGRIN; ANIMALS; BASEMENT MEMBRANE; BONE DISEASES, DEVELOPMENTAL; COLLAGEN TYPE IV; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LAMININ; LUPUS NEPHRITIS; MECHANOTRANSDUCTION, CELLULAR; MEMBRANE GLYCOPROTEINS; MUTATION; PROTEIN ISOFORMS;

EID: 85011019946     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2016.12.009     Document Type: Review

References (89)

1. [1] Bowman, W., On the minute structure and movements of voluntary muscle. Phil. Trans. R. Soc. Lond. Biol. Sci. 130 (1840), 457–494.
2. [2] Naba, A., Clauser, K.R., Ding, H., Whittaker, C.A., Carr, S.A., Hynes, R.O., The extracellular matrix: tools and insights for the “omics” era. Matrix Biol. 49 (2016), 10–24.
3. [3] Murphy-Ullrich, J.E., Sage, E.H., Revisiting the matricellular concept. Matrix Biol. 37 (2014), 1–14.
4. [4] Nichols, S.A., Roberts, B.W., Richter, D.J., Fairclough, S.R., King, N., Origin of metazoan cadherin diversity and the antiquity of the classical cadherin/beta-catenin complex. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 13046–13051.
5. [5] Fahey, B., Degnan, B.M., Origin and evolution of laminin gene family diversity. Mol. Biol. Evol. 29 (2012), 1823–1836.
6. [6] Yurchenco, P.D., Amenta, P.S., Patton, B.L., Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biol. 22 (2004), 521–538.
7. [7] Miner, J.H., Yurchenco, P.D., Laminin functions in tissue morphogenesis. Annu. Rev. Cell Dev. Biol. 20 (2004), 255–284.
8. [8] Smyth, N., Vatansever, H.S., Murray, P., Meyer, M., Frie, C., Paulsson, M., et al. Absence of basement membranes after targeting the LAMC1 gene results in embryonic lethality due to failure of endoderm differentiation. J. Cell Biol. 144 (1999), 151–160.
9. [9] Yurchenco, P.D., Patton, B.L., Developmental and pathogenic mechanisms of basement membrane assembly. Curr. Pharm. Des. 15 (2009), 1277–1294.
10. [10] Khoshnoodi, J., Pedchenko, V., Hudson, B.G., Mammalian collagen IV. Microsc. Res. Tech. 71 (2008), 357–370.
11. [11] Randles, M.J., Humphries, M.J., Lennon, R., Proteomic definitions of basement membrane composition in health and disease. Matrix Biol. 57-58 (2017), 12–28.
12. [12] Yurchenco, P.D., Basement membranes: cell scaffoldings and signaling platforms. Cold Spring Harb. Perspect. Biol., 3, 2011.
13. [13] Fleger-Weckmann, A., Ustun, Y., Kloepper, J., Paus, R., Bloch, W., Chen, Z.L., et al. Deletion of the epidermis derived laminin gamma1 chain leads to defects in the regulation of late hair morphogenesis. Matrix Biol. 56 (2016), 42–56.
14. [14] Wegner, J., Loser, K., Apsite, G., Nischt, R., Eckes, B., Krieg, T., et al. Laminin alpha5 in the keratinocyte basement membrane is required for epidermal-dermal intercommunication. Matrix Biol. 56 (2016), 24–41.
15. [15] Sun, Z., Guo, S.S., Fassler, R., Integrin-mediated mechanotransduction. J. Cell Biol. 215 (2016), 445–456.
16. [16] Engler, A.J., Sen, S., Sweeney, H.L., Discher, D.E., Matrix elasticity directs stem cell lineage specification. Cell 126 (2006), 677–689.
17. [17] Jimenez-Mallebrera, C., Brown, S.C., Sewry, C.A., Muntoni, F., Congenital muscular dystrophy: molecular and cellular aspects. Cell. Mol. Life Sci. 62 (2005), 809–823.
18. [18] Yurchenco, P.D., Integrating activities of laminins that drive basement membrane assembly and function. Curr. Top. Membr. 76 (2015), 1–30.
19. [19] Nakano, A., Chao, S.C., Pulkkinen, L., Murrell, D., Bruckner-Tuderman, L., Pfendner, E., et al. Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes. Hum. Genet. 110 (2002), 41–51.
20. [20] Matejas, V., Hinkes, B., Alkandari, F., Al-Gazali, L., Annexstad, E., Aytac, M.B., et al. Mutations in the human laminin beta2 (LAMB2) gene and the associated phenotypic spectrum. Hum. Mutat. 31 (2010), 992–1002.
21. [21] Gale, D.P., Oygar, D.D., Lin, F., Oygar, P.D., Khan, N., Connor, T.M., et al. A novel COL4A1 frameshift mutation in familial kidney disease: the importance of the C-terminal NC1 domain of type IV collagen. Nephrol. Dial. Transplant. 31 (2016), 1908–1914.
22. [22] Gould, D.B., Phalan, F.C., Breedveld, G.J., Van Mil, S.E., Smith, R.S., Schimenti, J.C., et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science 308 (2005), 1167–1171.
23. [23] Gould, D.B., Phalan, F.C., VanMil, S.E., Sundberg, J.P., Vahedi, K., Massin, P., et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N. Engl. J. Med. 354 (2006), 1489–1496.
24. [24] Alavi, M.V., Mao, M., Pawlikowski, B.T., Kvezereli, M., Duncan, J.L., Libby, R.T., et al. Col4a1 mutations cause progressive retinal neovascular defects and retinopathy. Sci. Rep., 6, 2016, 18602.
25. [25] Jeanne, M., Gould, D.B., Genotype-phenotype correlations in pathology caused by collagen type IV alpha 1 and 2 mutations. Matrix Biol. 57-58 (2017), 29–44.
26. [26] Cosgrove, D., Liu, S., Collagen IV diseases: a focus on the glomerular basement membrane in Alport syndrome. Matrix Biol. 57-58 (2017), 45–54.
27. [27] Butterfield, R.J., Foley, A.R., Dastgir, J., Asman, S., Dunn, D.M., Zou, Y., et al. Position of glycine substitutions in the triple helix of COL6A1, COL6A2, and COL6A3 is correlated with severity and mode of inheritance in collagen VI myopathies. Hum. Mutat. 34 (2013), 1558–1567.
28. [28] Ryynänen, M., Ryynänen, J., Solberg, S., Iozzo, R.V., Knowlton, R.G., Uitto, J., Genetic linkage of Type VII collagen (COL7A1) to dominant dystrophic epidermolysis bullosa in families with abnormal anchoring fibrils. J. Clin. Invest. 89 (1992), 974–980.
29. [29] Vahidnezhad, H., Youssefian, L., Zeinali, S., Saeidian, A.H., Sotudeh, S., Mozafari, N., et al. Dystrophic epidermolysis bullosa: COL7A1 mutation landscape in a multi-ethnic cohort of 152 extended families with high degree of customary consanguineous marriages. J. Investig. Dermatol., 2016.
30. [30] Oliver, V.F., van Bysterveldt, K.A., Cadzow, M., Steger, B., Romano, V., Markie, D., et al. A COL17A1 splice-altering mutation is prevalent in inherited recurrent corneal erosions. Ophthalmology 123 (2016), 709–722.
31. [31] Jonsson, F., Bystrom, B., Davidson, A.E., Backman, L.J., Kellgren, T.G., Tuft, S.J., et al. Mutations in collagen, type XVII, alpha 1 (COL17A1) cause epithelial recurrent erosion dystrophy (ERED). Hum. Mutat. 36 (2015), 463–473.
32. [32] Bauer, J.W., Lanschuetzer, C., Type XVII collagen gene mutations in junctional epidermolysis bullosa and prospects for gene therapy. Clin. Exp. Dermatol. 28 (2003), 53–60.
33. [33] Suzuki, O., Kague, E., Bagatini, K., Tu, H., Heljasvaara, R., Carvalhaes, L., et al. Novel pathogenic mutations and skin biopsy analysis in Knobloch syndrome. Mol. Vis. 15 (2009), 801–809.
34. [34] Heljasvaara, R., Aikio, M., Ruotsalainen, H., Pihlajaniemi, T., Collagen XVIII in tissue homeostasis and dysregulation - lessons learned from model organisms and human patients. Matrix Biol. 57-58 (2017), 55–75.
35. [35] Suzuki, O.T., Sertie, A.L., Der, K., Kok, V.F., Carpenter, M., Murray, J., et al. Molecular analysis of collagen XVIII reveals novel mutations, presence of a third isoform, and possible genetic heterogeneity in Knobloch syndrome. Am. J. Hum. Genet. 71 (2002), 1320–1329.
36. [36] Lin, Y., Zhang, S., Rehn, M., Itaranta, P., Tuukkanen, J., Heljasvaara, R., et al. Induced repatterning of type XVIII collagen expression in ureter bud from kidney to lung type: association with sonic hedgehog and ectopic surfactant protein C. Development 128 (2001), 1573–1585.
37. [37] Arikawa-Hirasawa, E., Wilcox, W.R., Le, A.H., Silverman, N., Govindraj, P., Hassell, J.R., et al. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat. Genet. 27 (2001), 431–434.
38. [38] Arikawa-Hirasawa, E., Le, A.H., Nishino, I., Nonaka, I., Ho, N.C., Francomano, C.A., et al. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am. J. Hum. Genet. 70 (2002), 1368–1375.
39. [39] Arikawa-Hirasawa, E., Wilcox, W.R., Yamada, Y., Dyssegmental dysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage development. Am. J. Med. Genet. 106 (2001), 254–257.
40. [40] Nicole, S., Davoine, C.-S., Topaloglu, H., Cattolico, L., Barral, D., Beighton, P., et al. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat. Genet. 26 (2000), 480–483.
41. [41] Huze, C., Bauche, S., Richard, P., Chevessier, F., Goillot, E., Gaudon, K., et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am. J. Hum. Genet. 85 (2009), 155–167.
42. [42] Maselli, R.A., Fernandez, J.M., Arredondo, J., Navarro, C., Ngo, M., Beeson, D., et al. LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin. Hum. Genet. 131 (2012), 1123–1135.
43. [43] Rudnicka, L., Varga, J., Christiano, A.M., Iozzo, R.V., Jimenez, S.A., Uitto, J., Elevated expression of type VII collagen in the skin of patients with systemic sclerosis. J. Clin. Invest. 93 (1994), 1709–1715.
44. [44] McCarthy, K.J., The basement membrane proteoglycans perlecan and agrin: something old, something new. Curr. Top. Membr. 76 (2015), 255–303.
45. [45] Wijeratne, S.S., Martinez, J.R., Grindel, B.J., Frey, E.W., Li, J., Wnag, K., et al. Single molecule force measurements of perlecan/HSPG2: a key component of the osteocyte pericellular matrix. Matrix Biol. 50 (2016), 27–38.
46. [46] Lord, M.S., Chuang, C.Y., Melrose, J., Davies, M.J., Iozzo, R.V., Whitelock, J.M., The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling. Matrix Biol. 35 (2014), 112–122.
47. [47] Iozzo, R.V., Basement membrane proteoglycans: from cellar to ceiling. Nat. Rev. Mol. Cell Biol. 6 (2005), 646–656.
48. [48] Iozzo, R.V., Schaefer, L., Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 42 (2015), 11–55.
49. [49] Zoeller, J.J., McQuillan, A., Whitelock, J., Ho, S.-Y., Iozzo, R.V., A central function for perlecan in skeletal muscle and cardiovascular development. J. Cell Biol. 181 (2008), 381–394.
50. [50] Zoeller, J.J., Whitelock, J., Iozzo, R.V., Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol. 28 (2009), 284–291.
51. [51] Iozzo, R.V., Zoeller, J.J., Nyström, A., Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol. Cell 27 (2009), 503–513.
52. [52] Baghy, K., Tatrai, P., Regos, E., Kovalszky, I., Proteoglycans in liver cancer. World J. Gastroenterol. 22 (2016), 379–393.
53. [53] Farach-Carson, M.C., Warren, C.R., Harrington, D.A., Carson, D.D., Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. Matrix Biol. 34 (2014), 64–79.
54. [54] Bix, G., Fu, J., Gonzalez, E., Macro, L., Barker, A., Campbell, S., et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through the α2β1 integrin. J. Cell Biol. 166 (2004), 97–109.
55. [55] Bix, G., Castello, R., Burrows, M., Zoeller, J.J., Weech, M., Iozzo, R.A., et al. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J. Natl. Cancer Inst. 98 (2006), 1634–1646.
56. [56] Bix, G., Iozzo, R.V., Matrix revolutions: “tails” of basement-membrane components with angiostatic functions. Trends Cell Biol. 15 (2005), 52–60.
57. [57] Woodall, B.P., Nyström, A., Iozzo, R.A., Eble, J.A., Niland, S., Krieg, T., et al. Integrin α2β1 is the required receptor for endorepellin angiostatic activity. J. Biol. Chem. 283 (2008), 2335–2343.
58. [58] Goyal, A., Pal, N., Concannon, M., Paulk, M., Doran, M., Poluzzi, C., et al. Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2). J. Biol. Chem. 286 (2011), 25947–25962.
59. [59] Douglass, S., Goyal, A., Iozzo, R.V., The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy. Connect. Tissue Res. 19 (2015), 1–11.
60. [60] Poluzzi, C., Iozzo, R.V., Schaefer, L., Endostatin and endorepellin: a common route of action for similar angiostatic cancer avengers. Adv. Drug Deliv. Rev. 97 (2016), 156–173.
61. [61] Poluzzi, C., Casulli, J., Goyal, A., Mercer, T.J., Neill, T., Iozzo, R.V., Endorepellin evokes autophagy in endothelial cells. J. Biol. Chem. 289 (2014), 16114–16128.
62. [62] Goyal, A., Gubbiotti, M.A., Chery, D.R., Han, L., Iozzo, R.V., Endorepellin-evoked autophagy contributes to angiostasis. J. Biol. Chem. 291 (2016), 19245–19256.
63. [63] Ning, L., Xu, Z., Furuya, N., Nonaka, R., Yamada, Y., Arikawa-Hirasawa, E., Perlecan inhibits autophagy to maintain muscle homeostasis in mouse soleus muscle. Matrix Biol. 48 (2015), 26–35.
64. [64] Gubbiotti, M.A., Iozzo, R.V., Proteoglycans regulate autophagy via outside-in signaling: an emerging new concept. Matrix Biol. 48 (2015), 6–13.
65. [65] Kvist, A.J., Johnson, A.E., Mörgelin, M., Gustafsson, E., Bengtsson, E., Lindblom, K., et al. Chondroitin sulfate perlecan enhances collagen fibril formation. Implications for perlecan chondrodysplasias. J. Biol. Chem. 281 (2006), 33127–33139.
66. [66] Arpino, V., Brock, M., Gill, S.E., The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 44–46 (2015), 247–254.
67. [67] Wells, J.M., Gaggar, A., Blalock, J.E., MMP generated matrikines. Matrix Biol. 44–46 (2015), 122–129.
68. [68] Deryugina, E.I., Quigley, J.P., Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 44–46 (2015), 94–112.
69. [69] Rohani, M.G., Parks, W.C., Matrix remodeling by MMPs during wound repair. Matrix Biol. 44–46 (2015), 113–121.
70. [70] Duarte, S., Baber, J., Fujii, T., Coito, A.J., Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol. 44–46 (2015), 147–156.
71. [71] Eckhard, U., Huesgen, P.F., Schilling, O., Bellac, C.L., Butler, G.S., Cox, J.H., et al. Active site specificity profiling of the matrix metalloproteinase family: proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. Matrix Biol. 49 (2016), 37–60.
72. [72] Muir, A.M., Massoudi, D., Nguyen, N., Keene, D.R., Lee, S.J., Birk, D.E., et al. BMP1-like proteinases are essential to the structure and wound healing of skin. Matrix Biol. 56 (2016), 114–131.
73. [73] Mongiat, M., Sweeney, S., San Antonio, J.D., Fu, J., Iozzo, R.V., Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 278 (2003), 4238–4249.
74. [74] Gonzalez, E.M., Reed, C.C., Bix, G., Fu, J., Zhang, Y., Gopalakrishnan, B., et al. BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J. Biol. Chem. 280 (2005), 7080–7087.
75. [75] O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997), 277–285.
76. [76] Grindel, B., Li, Q., Arnold, R., Petros, J., Zayzafoon, M., Muldoon, M., et al. Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients. Oncotarget 7 (2016), 10433–10447.
77. [77] Farach-Carson, M.C., Brown, A.C., Lynam, M., Safran, J.B., Carson, D.D., A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation. Matrix Biol. 27 (2008), 150–160.
78. [78] Bezakova, G., Rüegg, M.A., New insights into the roles of agrin. Nat. Rev. Mol. Cell Biol. 4 (2003), 295–308.
79. [79] Gesemann, M., Brancaccio, A., Schumacher, B., Ruegg, M.A., Agrin is a high-affinity binding protein of dystroglycan in non-muscle tissue. J. Biol. Chem. 273 (1998), 600–605.
80. [80] McKee, K.K., Yang, D.H., Patel, R., Chen, Z.L., Strickland, S., Takagi, J., et al. Schwann cell myelination requires integration of laminin activities. J. Cell Sci. 125 (2012), 4609–4619.
81. [81] Moll, J., Barzaghi, P., Lin, S., Bezakova, G., Lochmuller, H., Engvall, E., et al. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 413 (2001), 302–307.
82. [82] McKee, K.K., Capizzi, S., Yurchenco, P.D., Scaffold-forming and adhesive contributions of synthetic laminin-binding proteins to basement membrane assembly. J. Biol. Chem. 284 (2009), 8984–8994.
83. [83] Thadikkaran, L., Crettaz, D., Siegenthaler, M.A., Gallot, D., Sapin, V., Iozzo, R.V., et al. The role of proteomics in the assessment of premature rupture of fetal membranes. Clin. Chim. Acta 360 (2005), 27–36.
84. [84] Stephan, A., Mateos, J.M., Kozlov, S.V., Cinelli, P., Kistler, A.D., Hettwer, S., et al. Neurotrypsin cleaves agrin locally at the synapse. FASEB J. 22 (2008), 1861–1873.
85. [85] Oda, O., Shinzato, T., Ohbayashi, K., Takai, I., Kunimatsu, M., Maeda, K., et al. Purification and characterization of perlecan fragment in urine of end-stage renal failure patients. Clin. Chim. Acta 255 (1996), 119–132.
86. [86] O'Riordan, E., Orlova, T.N., Mendelev, N., Patschan, D., Kemp, R., Chander, P.N., et al. Urinary proteomic analysis of chronic renal allograft nephropathy. Proteomics Clin. Appl. 2 (2008), 1025–1035.
87. [87] Tsangaris, G.T., Karamessinis, P., Kolialexi, A., Garbis, S.D., Antsaklis, A., Mavrou, A., et al. Proteomic analysis of amniotic fluid in pregnancies with Down syndrome. Proteomics 6 (2006), 4410–4419.
88. [88] Chang, J.W., Kang, U.-B., Kim, D.H., Yi, J.K., Lee, J.W., Noh, D.-Y., et al. Identification of circulating endorepellin LG3 fragment: potential use as a serological biomarker for breast cancer. Proteomics Clin. Appl. 2 (2008), 23–32.
89. [89] Marshall, C.B., Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?. Am. J. Physiol. Ren. Physiol. 311 (2016), F831–F843.